Skip to main content
SpringerLink
Log in

Reossification of osteolytic metastases at the acetabulum following gefitinib and multidisciplinary treatment for lung cancer: a case report with autopsy findings

  • Case Report
  • Published:
Journal of Orthopaedic Science

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Zukawa M, Nakano M, Hirano N, Mizuhashi K, Kanamori M. The effectiveness of gefitinib on spinal metastases of lung cancer—report of two cases. Asian Spine J. 2008;2:109–13.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Yamashita Y, Aoki T, Hanagiri T, Yoshii C, Mukae H, Uramoto H, Korogi Y. Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: a sign of favorable therapeutic response. Skelet Radiol. 2012;41:409–14.

    Article  Google Scholar 

  3. Kijima T, Fujii Y, Suyama T, Okubo Y, Yonese J, Fukui I. Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report. Int J Urol. 2008;15:546–7.

    Article  PubMed  Google Scholar 

  4. Osanai T, Tsuchiya T, Ogino T, Nakahara K. Long-term prevention of skeletal complications by pamidronate in a patient with bone metastasis from endometrial carcinoma: a case report. Gynecol Oncol. 2006;100:195–7.

    Article  PubMed  Google Scholar 

  5. Normanno N, De Luca, Aldinucci D, Maiello MR, Mancino M, D’Antonio A, De Filippi R, Pinto A. Gefitinib inhibits the ability of human bone marrow stromal cells to reduce osteoclast differentiation; implications for the pathologenesis and treatment of bone metastasis. Endocr Ralat Cancer. 2005;12:471–82.

    Article  CAS  Google Scholar 

  6. Normanno N, Gullick WJ. Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocr Relat Cancer. 2006;13:3–6.

    Article  CAS  PubMed  Google Scholar 

  7. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer sci. 2007;98:1817–24.

    Article  CAS  PubMed  Google Scholar 

  8. Clézardin P, Fournier P, Boissier S, Peyruchaud O. In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem. 2003;10:173–80.

    Article  PubMed  Google Scholar 

  9. Koto K, Horie N, Kimura S, Murata H, Sakabe T, Matsui T, Watanabe M, Adachi S, Maekawa T, Fushiki S, Kubo T. Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Lett. 2009;274:271–8.

    Article  CAS  PubMed  Google Scholar 

  10. Koto K, Murata H, Kimura S, Horie N, Matsui T, Nishigaki Y, Ryu K, Sakabe T, Ashihara E, Maekawa T, Fushiki S, Kubo T. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol Rep. 2010;24:233–9.

    CAS  PubMed  Google Scholar 

  11. Krempien R, Huber PE, Harms W, Treiber M, Wannenmacher M, Krempien B. Combination of early bisphosphonate administration and irradiation leads to improved remineralization and restabilization of osteolytic bone metastases in an animal tumor model. Cancer. 2003;98:1318–24.

    Article  CAS  PubMed  Google Scholar 

  12. Kijima T, Fujii Y, Suyama T, Okubo Y, Yamamoto S, Masuda H, Yonese J, Fukui I. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int. 2009;103:620–4.

    Article  CAS  PubMed  Google Scholar 

  13. Ricciardi S, de Marinis F. Treatment of bone metastases in lung cancer: the actual role of zoledronic acid. Rev Recent Clin Trials. 2009;4:205–11.

    Article  CAS  PubMed  Google Scholar 

  14. Moore KL, Persaud TVN, Torchia MG. Skeletal system. The developing human. 9th ed. Philadelphia: Elsevier; 2013. p. 343–61.

    Google Scholar 

  15. Kierszenbaum AL, Tres LL. Oeteogenesis. Histology and Cell Biology: an introduction to Pathology. 3rd ed. Philadelphia: Elsevier; 2012. p. 151–68.

    Book  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Orthopedic Surgery, Hamamatsu Medical Center, 328 Tomitsuka-cho, Hamamatsu, Shizuoka, 432-8580, Japan

    Yasuzumi Kishimoto & Toshiki Iwase

  2. Department of Respirology, Hamamatsu Medical Center, Hamamatsu, Japan

    Toshiaki Yano

  3. Department of Pathology, Hamamatsu Medical Center, Hamamatsu, Japan

    Hiroki Mori

Authors
  1. Yasuzumi Kishimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshiki Iwase
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toshiaki Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroki Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuzumi Kishimoto.

About this article

Cite this article

Kishimoto, Y., Iwase, T., Yano, T. et al. Reossification of osteolytic metastases at the acetabulum following gefitinib and multidisciplinary treatment for lung cancer: a case report with autopsy findings. J Orthop Sci 20, 914–918 (2015). https://doi.org/10.1007/s00776-014-0562-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00776-014-0562-y

Keywords

Search

Navigation